SOUTH SAN FRANCISCO, Calif., May 2, 2016 (GLOBE NEWSWIRE) -- Tobira Therapeutics, Inc. (NASDAQ:TBRA), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and inflammatory diseases, will report financial results for the quarter ended March 31, 2016 after market close on Monday May, 9 2016. The company will conduct a conference call and an audio webcast at 1:30 pm Pacific Time (4:30 pm Eastern Time) on the same day.
Date: May 9, 2016
Time: 1:30 PM PT
Listen via Internet: http://ir.tobiratx.com/
Schedule this webcast into MS-Outlook calendar (click open when prompted):
http://apps.shareholder.com/PNWOutlook/t.aspx?m=71324&k=B42CB87C
Toll-free: 1 (855) 638-8858
International: +1 (707) 294-1299
Access code: 99831682
A webcast replay will be available on the Tobira Web site for 30 days. A telephone replay will be available for 48 hours following the conclusion of the call by dialing 1 (855) 859-2056 for domestic callers, or +1 (404) 537-3406 for international callers, and entering reservation code 99831682.
About Tobira Therapeutics, Inc.
Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and HIV. The company's lead product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and as an adjunctive therapy to standard of care in HIV. Tobira's pipeline also includes evogliptin, a selective DPP-4 inhibitor, which it plans to develop for NASH in combination with CVC. Learn more about Tobira at http://www.tobiratx.com.
Tobira(R) is a registered trademark owned by Tobira Therapeutics, Inc.
(c)2016 Tobira Therapeutics, Inc. All Rights Reserved.